Formulary Search Results for: CALCIUM AND VITAMIN D
6.1.2.3 Incretin mimetics - View Category
Restrictions:
Use in the treatment of type 2 diabetes mellitus (T2DM) is restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes for use in addition to other anti-diabetic medicines, or as an add-on to basal insulin.
Prescribing Notes:
- Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
6.1.2.6 Dipeptidylpeptidase-4 Inhibitors - View Category
Restrictions:
Restricted to the treatment of type 2 diabetes in adults in combination with metformin when the use of a sulfonylurea is inappropriate.
Combination preparations are further restricted to use only in those patients who have demonstrable compliance issues with the separate constituents
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
6.3.2 Glucocorticoid therapy - View Category
6.5.2 Posterior pituitary hormones and antagonists - View Category
6.6.2 Bisphosphonates and other drugs affecting bone metabolism - View Category
13.9.1 Shampoo preparations - View Category
Prescribing Notes:
For use in seborrhoeic scalp conditions like dermatitis. Contains benzalkonium chloride 0.5%
6.4.1.1.1.1 Sequential combined therapy (cyclical) - View Category
6.4.1.1.1.2 Continuous combined therapy - View Category
6.6.2 Bisphosphonates and other drugs affecting bone metabolism - View Category
Restrictions:
See Prescribing notes for Formulary indications and restrictions on use.
Prescribing Notes:
Formulary Indications:
- Osteoporosis: Use in the treatment of osteoporosis in postmenopausal women is restricted to use in those patients for whom oral bisphosphonates are unsuitable, contraindicated or not tolerated in accordance with local protocol. A shared care agreement is in place for this indication and can be accessed here.
- Skeletal-related events: The prevention of skeletal related events in adults with bone metastases from solid tumours is restricted to specialist use in accordance with regional protocol where zoledronic acid is not appropriate (for example, due to renal impairment or venous access problems). Use for this indication remains specialist use only.
Non-Formulary indications:
The following indications are not recommended by SMC and remain non-formulary:
- Bone loss in prostate cancer: use in the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
- Osteoporosis in men at increased risk of fractures.
- Giant cell tumour of bone: in adults and skeletally mature adolescents when the condition is unresectable or where surgical resection is likely to result in severe morbidity.
- Prevention of skeletal related events in adults with haematological malignancies involving bone.
- Bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
SMC advice pertaining to denosumab can be accessed here.
NICE Multiple Technology Appraisals pertaining to denosumab can be accessed here.
Near Patient Testing (NPT) arrangements for GPs may be in place for this medicine. See the relevant section in the Prescribing Resources page for current information.
